Clinical Trial Update: Evaluate Tolerability and Safety of BD03 for Prevention of CMV and BKV Reactivation in Kidney Transplant Recipient [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the tolerability and safety of BD03 to prevent cytomegalovirus and BK virus reactivation in kidney transplant recipients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bk Virus Infection
• Cytomegalovirus Infection

Drugs mentioned

• BD03

Snippet

Sponsor: SL VAXiGEN | Conditions: Cytomegalovirus Infections, Preventation of Cytomegalovirus Reactivation | Phase 1 | Status: UNKNOWN